Member Info for BasilAlderman

I'm with you Bfdinvestor. If GST can replicate with the Angra business what CABP has achieved then investors here will be very pleased. CABP is forecasting total income up by 25% from £109.4 million last year. Then you add the GS20 entity in to the equation and GST's overall income could really start to rocket once the soft launch has completed. If CABP has a market cap of £240 Million and GST has a current market cap of just £22 Million you can see what's likely to happen with our MCAP and share price. Exciting times ahead here.

What's exciting me is that with FDA approval pharma shares soar. RENX rose from 75p - 155p in two weeks. i.e. a 100% gain. Plus the shares of Reata Pharmaceuticals multi-bagged x 3 in just one day last year year after the FDA gave its approval. Their share price has subsequently multi-bagged over 5 times since March of last year. Therefore a share price for Hemogenyx of 12-15p is possible on FDA news and then going in to clinical trials. Having the former boss of the FDA in the Prevail camp is also a master stroke for Hemogenyx as the help and advice from Prevail will surely be critical in FDA lifting the CH.

Thanks to those posting on here about Boundless Bio and 737. Those that have been here for many moons will know that in combination with Dexamethasone SRA 737 works. We know In combination with AstraZeneca's WEE1 inhibitor Adavosertib SRA737 works. We know that in combination with Merck’s Keytruda SRA 737 works and

we know that in combination with Eli Lillys Gemcitabine SRA737 works. It is a no-brainer that Boundless Bio (who have connections to Sierra Onc) would want to licence SRA 737 (CCT-245737). It makes perfect sense. What didn't make any sense at the time was Sierra putting it on the back burner when the data was so positive. The only conclusion was they didn't have the funds to develop it? Boundless Bio on the hand appear to be adept at cash raises. This bodes well for 737.

Homer, 30p is certainly a possibility and will make newbies buying at these low bargain prices very happy. Don't forget that N4P has been over 30p in the past. I'm hoping for a Tempest Therapeutics style rise for N4P. They went up x39 last year in a couple of trading days. See Bloomberg headline, below:

"Near-4,000% Surge Catapults One Tiny Biotech Firm to Record Week. Tempest adds more than $120 million in market value in October from gain"

Any company that is "to grow revenues substantially" requires a very well connected NED. His experience at Natwest Securities, Merrill Lynch, Tristone Capital & Macquarie is yet another excellent stepping stone. This has 20p a share in 2024 written all over it.

The market works on forward looking figures so a company saying it it going to grow its revenues "Substantially" next year is clearly positive, not just today but moving forward. Substantial by the way is, as per the Oxford dictionary, the same as:

considerable

significant

vast

solid

massive (as in Ray)

marked

serious

notable

monumental

extraordinary

i.e. pick any of the above and we will see in 2024 considerable, significant, vast, solid, massive, marked, serious, notable, monumental, extraordinary and substantial growth.

Lets hope Nigel can pull a rabbit out of the hat for N4P shareholders.

https://www.lse.co.uk/news/n4-pharma-rises-on-successful-results-from-nuvec-administration-4zxavtayk1i05x9.html

Jules, This was probably the worst AGM I have ever viewed. The BOD's body language was very poor and the evasive answers could have been from the TV series Yes Prime Minister, with Sir Humphrey and Bernard. I am actually lost for words. I also agree with the shareholder who said that Tim should be moved sideways to a scientific role and a CEO appointed to run the business. They may well be great scientists but their business skills - which includes the ability to communicate and inspire confidence - needs addressing before it is too late.

Up in Newcastle tonight with clients to watch The Toon army in the Champions League v AC Milan. As they used to chant in thevAshley era Sack The Board Sack The Board. Suzy Dilly this is not acceptable.

It is pretty obvious. They are getting ready for the forward looking section of the GST results (according to Bloomberg due out on Monday the 18th Dec) and will make significant profits when the GST share price surges next week.

Bloomberg has just updated the GST interim results date to Monday 18th Dec. So, we have 7 trading days left until the forward looking section of the results electrifies the wider market with what we already know on this forum.

The $10 Billion AbbVie deal is a great reminder of the big bucks major players will pay for smaller rivals. It will be significant news too once we officially become a clinical stage company . We are fast approaching that moment.

With a VAL Theoremrx deal 40 pence - 60 pence a share is very likely. This could be happening within days if the anticipated EUDA transaction is signed off this week. We've been higher than 60 pence without news before. With a positive VAL Theoremrx licencing deal it stands to reason that we should exceed the previous highs of a couple of years ago.

5 pence a share on interim results results day (20th December ish) is what I am expecting.

Num4, I hold 128,000 shares (6.4million pre the ridiculous tinkering). I'm here for a £Billion takeover. However long it takes.

0.71p today. The lowest ever share price for N4P since it listed on AIM. That's some going. Over 30p a share to 0.71. History very much repeating itself I see from NT's previous AIM plc. Still the pension pot will have been topped up, the mortgage paid off etc

20p today could easily become 40p - 60p this week with a Theoremrx deal.

This is actually very interesting for the VAL share price as it looks as though the timing of todays announcement is going to coincide with a Theoremrx announcement very soon. i.e. The VAL share price gets a boost today from its 401 licencing news and then we see a a really big rise with a deal with Theoremrx.

I was invested in Oxford Pharmascience, which Nigel was CEO of. He might well pull a rabbit out of the hat for N4P shareholders. Who knows? All I have seen with N4P is a repeat of what happened with Oxford Pharmascience. Lots of hype but a gradual decline in the share price. N4P has gone from over 25p in June 2018 to sub 1 p today. I hope he delivers this time around.

I was invested in Oxford Pharmascience, which NT, was CEO of. Nigel might pull a rabbit out of the hat for N4P shareholders. Who knows? All I have seen with